AstraZeneca’s Imfinzi combination cuts death risk 42% in bladder cancer trial

• AstraZeneca’s Imfinzi with enfortumab vedotin improved survival versus standard care in the Phase III VOLGA trial in muscle-invasive bladder cancer.
• The regimen reduced progression or recurrence in patients ineligible for cisplatin-based chemotherapy or who refused it.
• No new safety signals emerged, though severe adverse events were more common with the combination.
• Results will be presented today at the ESMO Congress 2026 in Madrid; findings were simultaneously published in The New England Journal of Medicine.
• The FDA granted the regimen priority review in September 2026 based on these findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610241030BIZWIRE_USPR_____20261024_BW759920) on October 24, 2026, and is solely responsible for the information contained therein.